Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy

Fig. 4

Heatmap of CRC sequential somatic mutations and clinical characteristics. We divided the patients into two subgroups (G1 and G2). Patients with a better prognosis in the previous survival decision subgroup (C1, C2, and C3) formed subgroup G1; the patients with a worse prognosis (C4, C5, C6, and C7) formed subgroup G2. We show only the 22 sequential somatic mutations that distinguished the two subgroups based on LASSO regression

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us